AUTHORS
Maggie Viland, Ethan Chang2, Cuiqiyun Yang, MS3, Mackenzie K Heidkamp, MD4, Sean Rowell5, Jacqueline Perry, MPH6, Katherine Drascher7, Alexander Caraballo8, Zhi Yu, MB, PhD9, Wenjie Ma, MBBS, ScD10, Clifton C. Mo, MD11, Yuxin Liu, MD12, Shonali Midha, MD13, Omar Nadeem, MD14, Jacob Laubach, MD15, Paul G. Richardson, MD16, Kenneth Anderson, MD17, Catherine Marinac, PhD18, Nikhil Munshi, MD19, Irene M Ghobrial, MD20, David Drew, PhD21, Elizabeth O'Donnell, MD22
AFFILIATIONS
1 Massachusetts General Hospital, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Massachusetts General Hospital, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Massachusetts General Hospital, Boston, Massachusetts, United States
9 Massachusetts General Hospital, Boston, Massachusetts, United States
10 Massachusetts General Hospital, Boston, Massachusetts, United States
11 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
12 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
14 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
15 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
16 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
17 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
18 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
19 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
20 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
21 Massachusetts General Hospital, Boston, Massachusetts, United States
22 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ABSTRACT
Introduction
Multiple myeloma (MM) evolves from the precursor conditions monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Our team has previously demonstrated that immune dysregulation plays a key role in disease progression among the largest, most diverse cohort assembled of patients with precursor myeloma. In parallel, the gut microbiome has emerged as a key mediator of immune dysregulation in cancers and immunotherapy response, including preliminary evidence supporting a specific role in MM progression. Thus, the gut microbiome provides a target-rich environment for biomarker-based risk stratification. In the largest known cohort to-date, we evaluated gut microbial features associated with precursor myeloma (MGUS, SMM), and MM to identify microbial signatures associated with disease state and progression.
Methods
Participants were recruited through two ongoing IRB-approved prospective cohorts at the Dana-Farber Cancer Institute (IRB# 14-174 and 07-150). Stool samples were collected using validated at-home collection kits and questionnaires. Shotgun sequencing of stool metagenomes with 3 GB coverage was conducted using a validated Illumina-based Genomics Platform. Raw metagenomic data was processed to yield microbial community taxonomic and functional profiles using BioBakery v.3. Differences in gut community profiles were assessed using two approaches accounting for relevant covariates. First, we performed omnibus testing on dissimilarity matrices. Bray-Curtis dissimilarity matrices were calculated from species-level relative abundance tables and visualized with principal coordinate analysis (PCoA) to assess beta diversity shifts across treatment groups. P-values were correcting for multiple testing using the Benjamini-Hochberg false discovery rate procedure. Features were considered biologically meaningful at q < 0.25. Feature-level testing adjusting age and sex was performed using Multivariate Association with Linear Models v.3 (MaAsLin3).
Results
After sequencing, 100 MM, 99 SMM, and 114 MGUS patient stool samples were included. Median ages were 67, 65, and 65 years, respectively. 59% of MM, 48% SMM, and 35% MGUS were male and 86% of MM, 94% SMM, and 89% MGUS were white. Of patients with MM, 50% had undergone an autologous stem cell transplant and the mean number of therapies was 3 (SD 2.3). Patients with MGUS and SMM were treatment-naïve.
Species richness showed a marked difference between MM samples and MGUS (q=1.44×10⁻⁷) and SMM (q=1.62×10⁻⁶), while alpha-diversity did not differ significantly between MGUS and SMM (q=0.716). Bray-Curtis dissimilarity matrices further suggested differences in overall microbial community composition comparing MM to MGUS (q=0.0015) and SMM (0.0015), but not between MGUS and SMM (q=0.334). Consistent with other cancer types, the Firmicutes/Bacteroidetes ratios are reduced in MM compared to precursor conditions. Following multivariate adjustment, MM is associated with relative enrichment of Enterocloster clostridioformis, Blautia caecimuris, Flavonifractor plautii, Ruminococcus gnavus, Ruthenibacterium lactatiformans, Dysosmobacter welbionis species and depletion of Alistipes communis, Roseburia hominis, Blautia faecis, Alistipes shahii, Clostridiciaceae bacterium, and Fusicatenibacter saccharivorans compared to both precursor conditions (all q<0.05). No significant species-level differences in relative abundance (all q>0.05) were observed between SMM and MGUS. Pathway-level differences according to disease stage and the impact of treatment are ongoing and will be presented.
Conclusions
These findings indicate that MM is associated with reduced gut microbial richness, characterized by an overall reduction in the ratio of Firmicutes to Bacteroidetes that has previously been described as a negative prognostic marker for other cancer types. Although the lower microbiota diversity observed in MM may be partly attributable to treatment exposures in this cohort, these findings also highlight the need for further investigation into whether microbiome alterations may contribute to disease progression itself. Species-level differences between MM and precursor conditions suggest the possibility for microbial biomarkers of disease progression and warrant further study for mechanistic understanding and longitudinal validation to assess for their potential role in risk stratification.
DISCLOSURES
Elizabeth O'Donnell, MD: No relevant conflicts of interest to declare.